Literature DB >> 11319923

Generation of a flexible cell line with regulatable, high-level expression of HIV Gag/Pol particles capable of packaging HIV-derived vectors.

S Sparacio1, T Pfeiffer, H Schaal, V Bosch.   

Abstract

HIV-derived vectors are of potential clinical relevance due to their ability to transduce nondividing cells in vitro and in vivo. However, the generation of cell lines stably and reproducibly expressing high amounts of defined subviral particles, capable of packaging and transducing HIV-derived vectors, has been hampered by the cytotoxicity of some of the required gene products, in particular of the HIV-1 protease. The successful use of regulatable gene expression systems to overcome this problem requires that the remaining basally expressed gene product activity is below the threshold for cytotoxicity. To try to achieve this, we have consecutively introduced appropriate plasmids, encoding HIV rev and HIV gag/pol gene products, each under the control of separate ecdysone-inducible promoters, into human 293 cells. Using a protocol in which a specific HIV protease inhibitor, Saquinavir, was continuously present in the culture medium during selection, we could generate stable cell lines inducibly expressing high amounts of subviral particles. A cell line, termed 293-Rev/Gag/Pol(i), which has been characterized in more detail, inducibly releases, within 48 h postinduction, high amounts of HIV Gag/Pol particles (about 10 microg CA/ml). These HIV Gag/Pol particles can package and transduce third-generation HIV vectors to high titers. Thus, in addition to other applications, the 293-Rev/Gag/Pol(i) cell line represents a "founder" packaging cell line which, depending on the requirement, can be further modified to include specific transgene-encoding vector and targeting glycoprotein genes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11319923     DOI: 10.1006/mthe.2001.0296

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  11 in total

1.  RD2-MolPack-Chim3, a packaging cell line for stable production of lentiviral vectors for anti-HIV gene therapy.

Authors:  Anna Stornaiuolo; Bianca Maria Piovani; Sergio Bossi; Eleonora Zucchelli; Stefano Corna; Francesca Salvatori; Fulvio Mavilio; Claudio Bordignon; Gian Paolo Rizzardi; Chiara Bovolenta
Journal:  Hum Gene Ther Methods       Date:  2013-08-03       Impact factor: 2.396

2.  Efficient large volume lentiviral vector production using flow electroporation.

Authors:  Scott R Witting; Lin-Hong Li; Aparna Jasti; Cornell Allen; Kenneth Cornetta; James Brady; Rama Shivakumar; Madhusudan V Peshwa
Journal:  Hum Gene Ther       Date:  2011-10-24       Impact factor: 5.695

3.  Cancer Gene Therapy: Development and Production of Lentiviral Vectors for Gene Therapy.

Authors:  Ana S Coroadinha
Journal:  Methods Mol Biol       Date:  2022

4.  Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection.

Authors:  Robert E Throm; Annastasia A Ouma; Sheng Zhou; Anantharaman Chandrasekaran; Timothy Lockey; Michael Greene; Suk See De Ravin; Morvarid Moayeri; Harry L Malech; Brian P Sorrentino; John T Gray
Journal:  Blood       Date:  2009-03-13       Impact factor: 22.113

5.  Generation and characterization of a stable cell population releasing fluorescent HIV-1-based Virus Like Particles in an inducible way.

Authors:  Claudia Muratori; Paola D'Aloja; Fabiana Superti; Antonella Tinari; Nathalie Sol-Foulon; Sandra Sparacio; Valerie Bosch; Olivier Schwartz; Maurizio Federico
Journal:  BMC Biotechnol       Date:  2006-12-27       Impact factor: 2.563

Review 6.  Practical uses for ecdysteroids in mammals including humans: an update.

Authors:  R Lafont; L Dinan
Journal:  J Insect Sci       Date:  2003       Impact factor: 1.857

7.  Endogenous CCL2 neutralization restricts HIV-1 replication in primary human macrophages by inhibiting viral DNA accumulation.

Authors:  Michela Sabbatucci; Daniela Angela Covino; Cristina Purificato; Alessandra Mallano; Maurizio Federico; Jing Lu; Arturo Ottavio Rinaldi; Matteo Pellegrini; Roberta Bona; Zuleika Michelini; Andrea Cara; Stefano Vella; Sandra Gessani; Mauro Andreotti; Laura Fantuzzi
Journal:  Retrovirology       Date:  2015-01-22       Impact factor: 4.602

8.  HIV-protease inhibitors block the replication of both vesicular stomatitis and influenza viruses at an early post-entry replication step.

Authors:  Maurizio Federico
Journal:  Virology       Date:  2011-05-28       Impact factor: 3.616

9.  HPV-E7 delivered by engineered exosomes elicits a protective CD8⁺ T cell-mediated immune response.

Authors:  Paola Di Bonito; Barbara Ridolfi; Sandra Columba-Cabezas; Andrea Giovannelli; Chiara Chiozzini; Francesco Manfredi; Simona Anticoli; Claudia Arenaccio; Maurizio Federico
Journal:  Viruses       Date:  2015-03-09       Impact factor: 5.048

Review 10.  Production of lentiviral vectors.

Authors:  Otto-Wilhelm Merten; Matthias Hebben; Chiara Bovolenta
Journal:  Mol Ther Methods Clin Dev       Date:  2016-04-13       Impact factor: 6.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.